Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shenyang Pharma Univ. CYP1B1 compound B20
- Development stage
- Unknown
- Lead developer
- Shenyang Pharmaceutical University
01
Overview
Shenyang Pharma Univ. CYP1B1 compound B20: sourced facts only. name: "These comprehensive data position B20 as a promising compound for overcoming paclitaxel resistance via CYP1B1 inhibition." [PMID:40522756]; target: "These comprehensive data position B20 as a promising compound for overcoming paclitaxel resistance via CYP1B1 inhibition." [PMID:40522756]; developer: "Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China." [PMID:40522756]; stage: "Biological evaluations demonstrated the capacity of B20 to resensitize paclitaxel-resistant cells while maintaining favorable tumor/normal cell selectivity." [PMID:40522756]
02
Targets
CYP1B1 (Cytochrome P450 1B1)
Beyond the preview
Go deeper on Shenyang Pharma Univ. CYP1B1 compound B20.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shenyang Pharma Univ. CYP1B1 compound B20.